Korea Bio-Gen Co.Ltd Cash Flow-to-Debt Ratio
Korea Bio-Gen Co.Ltd cash flow-to-debt ratio. Korea Bio-Gen Co.Ltd (318000) has a Cash Flow-to-Debt Ratio of 0.25x as of June 2026, meaning its operating cash flow of ₩1.51 Billion could theoretically repay 0% of its total liabilities (₩6.11 Billion) in one year. Check Korea Bio-Gen Co.Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Korea Bio-Gen Co.Ltd (2017–2025)
Cash flow-to-debt ratio of Korea Bio-Gen Co.Ltd from 2017 to 2025. Historical debt coverage capacity for Korea Bio-Gen Co.Ltd across 9 annual periods. Check Korea Bio-Gen Co.Ltd (318000) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Korea Bio-Gen Co.Ltd Cash Flow-to-Debt Ratio by Year (2017–2025)
Korea Bio-Gen Co.Ltd cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Korea Bio-Gen Co.Ltd. For the full cash flow conversion analysis, see Korea Bio-Gen Co.Ltd cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 1.35x | ₩7.34 Billion | ₩5.42 Billion | ▲ +112.2% |
| 2024 | 0.64x | ₩4.29 Billion | ₩6.73 Billion | ▼ -73.7% |
| 2023 | 2.43x | ₩9.47 Billion | ₩3.90 Billion | ▲ +1082.5% |
| 2022 | 0.21x | ₩1.67 Billion | ₩8.13 Billion | ▼ -31.0% |
| 2021 | 0.30x | ₩3.09 Billion | ₩10.39 Billion | ▼ -66.5% |
| 2020 | 0.89x | ₩2.58 Billion | ₩2.91 Billion | ▼ -28.1% |
| 2019 | 1.24x | ₩3.05 Billion | ₩2.47 Billion | ▲ +449.4% |
| 2018 | 0.22x | ₩1.98 Billion | ₩8.83 Billion | ▲ +27.9% |
| 2017 | 0.18x | ₩1.38 Billion | ₩7.88 Billion | — |